Inari Medical announced positive two-year interim results from the CLOUT registry evaluating its ClotTriever system. Principal investigator Dr. David Dexter of Sentara Vascular Specialists in Norfolk, Virginia, presented the data at the American Venous Forum. Results represent the largest prospective, multi-center, two-year dataset in deep-vein thrombosis (DVT) since the ATTRACT trial, Inari said in a […]
Inari Medical
Inari Medical closes LimFlow acquisition
Inari Medical announced that it completed its acquisition of chronic limb-threatening ischemia (CLTI) treatment maker LimFlow. The Irvine, California–based company earlier this month announced plans to acquire LimFlow for up to $415 million. The deal came just weeks after Paris-based LimFlow won FDA premarket approval (PMA) for its breakthrough CLTI treatment. Inari Medical intends to […]
Inari Medical plans to buy LimFlow Medical for up to $415M
Inari Medical today announced a definitive agreement to purchase LimFlow Medical for up to $415 million. The deal comes just weeks after Paris-based LimFlow won FDA premarket approval (PMA) for its breakthrough system to treat chronic limb-threatening ischemia (CLTI). San Jose, California–based Inari said it expects to complete the acquisition by the end of 2023. […]
Inari Medical launches RevCore, Triever16 Curve catheters
Inari Medical today announced it launched two new catheters for venous stent thrombosis and venous thromboembolism. The Irvine, California-based company launched its RevCore thrombectomy catheter and the Triever16 Curve catheter. RevCore is a mechanical thrombectomy device for venous in-stent thrombosis, and Triever16 Curve is for pulmonary embolism and peripheral thrombectomy. “We are thrilled to announce […]
Analysts are bullish on Inari Medical following Q4 results
Inari Medical (Nasdaq:NARI) shares dipped today despite fourth-quarter results that left analysts excited for the coming year. Shares of NARI fell 3.5% at $55.34 apiece in midday trading today. MassDevice‘s MedTech 100 Index, which includes stocks of the world’s largest medical device companies, was up slightly. The Irvine, California-based thrombectomy device developer posted losses of […]
Inari Medical enrolls first patient in ClotTriever system trial for treating deep vein thrombosis
Inari Medical (Nasdaq:NARI) today announced that it enrolled the first patient in its Defiance trial for evaluating the ClotTriever system. In August 2022, Inari Medical announced the launch of its Defiance trial for comparing ClotTriever to anticoagulation. Those enrolled in the trial (300 patients total) only have iliofemoral deep vein thrombosis (DVT). The trial spans […]
Inari Medical rises on Street-beating Q3, increased guidance
Inari Medical (Nasdaq:NARI) shares ticked up after hours today on third-quarter results that topped the consensus forecast. The Irvine, California-based thrombectomy device developer posted losses of $10.2 million. That equals 19¢ per share on sales of $96.2 million for the three months ended Sept. 30, 2022. Inari registered a more than $7 million bottom-line deeper […]
Inari Medical reports positive outcomes from FlowTriever study
Inari Medical (Nasdaq:NARI) announced today that the FLASH registry evaluating its FlowTriever produced positive results. The company designed its FlowTriever for device retrieval and aspiration. The system treats pulmonary embolism (PE). FlowTriever non-surgically removes clots from peripheral blood vessels. Its uses include treatment for PE and clots in transit in the right atrium. It received […]
Inari Medical launches trial to assess ClotTriever system in deep vein thrombosis
Inari Medical (Nasdaq:NARI) announced that it will conduct a trial for its ClotTriever system for iliofemoral deep vein thrombosis (DVT). The Irvine, California-based company’s Defiance trial will compare ClotTriever to anticoagulation only for patients with iliofemoral DVT. Defiance will enroll 300 patients across up to 60 centers around the world. It represents Inari’s second randomized […]
Inari Medical to promote COO into CEO spot
Inari Medical (Nasdaq:NARI) announced this week that Drew Hykes will succeed Bill Hoffman as the company’s CEO. Hykes, who currently serves as COO at the venous-specific devices company, will succeed Hoffman, effective Jan. 1, 2023. He will also join Inari’s board, while Hoffman will continue to serve on the board as well. “Drew is a […]
Inari Medical to bring in up to $186.3M in stock offering
Inari Medical (Nasdaq:NARI) announced that it priced an underwritten public offering worth up to $186.3 million in proceeds. Irvine, California-based Inari Medical’s offering includes 2 million shares of its common stock at a public offering price of $81 per share before underwriting discounts and commissions. In addition, the company granted the underwriters a 30-day option […]